🚀 VC round data is live in beta, check it out!
Stayble Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Stayble Therapeutics and similar public comparables like Cannovum Cannabis, IO Biotech, GeNeuro, PharmaLundensis and more.
Stayble Therapeutics Overview
About Stayble Therapeutics
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
Founded
2015
HQ
Employees
3
Website
Sectors
Financials (LTM)
EV
$749K
Stayble Therapeutics Financials
Stayble Therapeutics reported last 12-month revenue of — and negative EBITDA of ($179K).
In the same LTM period, Stayble Therapeutics generated ($179K) in EBITDA losses.
Revenue (LTM)
Stayble Therapeutics P&L
In the most recent fiscal year, Stayble Therapeutics reported revenue of — and EBITDA of ($752K).
Stayble Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($179K) | XXX | ($752K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($756K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Stayble Therapeutics Stock Performance
Stayble Therapeutics has current market cap of $896K, and enterprise value of $749K.
Market Cap Evolution
Stayble Therapeutics' stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $749K | $896K | 0.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStayble Therapeutics Valuation Multiples
Stayble Therapeutics trades at (4.2x) EV/EBITDA.
EV / Revenue (LTM)
Stayble Therapeutics Financial Valuation Multiples
As of April 19, 2026, Stayble Therapeutics has market cap of $896K and EV of $749K.
Equity research analysts estimate Stayble Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stayble Therapeutics has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $896K | XXX | $896K | XXX | XXX | XXX |
| EV (current) | $749K | XXX | $749K | XXX | XXX | XXX |
| EV/EBITDA | (4.2x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | (4.2x) | XXX | (1.0x) | XXX | XXX | XXX |
| P/E | — | XXX | (1.2x) | XXX | XXX | XXX |
| EV/FCF | (2.8x) | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Stayble Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Stayble Therapeutics Margins & Growth Rates
Stayble Therapeutics' revenue in the last fiscal year grew by —.
Stayble Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Stayble Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (924%) | XXX | (259%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Stayble Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stayble Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cannovum Cannabis | XXX | XXX | XXX | XXX | XXX | XXX |
| IO Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| GeNeuro | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaLundensis | XXX | XXX | XXX | XXX | XXX | XXX |
| Nidhogg Resources Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stayble Therapeutics M&A Activity
Stayble Therapeutics acquired XXX companies to date.
Last acquisition by Stayble Therapeutics was on XXXXXXXX, XXXXX. Stayble Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Stayble Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStayble Therapeutics Investment Activity
Stayble Therapeutics invested in XXX companies to date.
Stayble Therapeutics made its latest investment on XXXXXXXX, XXXXX. Stayble Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Stayble Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Stayble Therapeutics
| When was Stayble Therapeutics founded? | Stayble Therapeutics was founded in 2015. |
| Where is Stayble Therapeutics headquartered? | Stayble Therapeutics is headquartered in Sweden. |
| How many employees does Stayble Therapeutics have? | As of today, Stayble Therapeutics has over 3 employees. |
| Is Stayble Therapeutics publicly listed? | Yes, Stayble Therapeutics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Stayble Therapeutics? | Stayble Therapeutics trades under STABL ticker. |
| When did Stayble Therapeutics go public? | Stayble Therapeutics went public in 2020. |
| Who are competitors of Stayble Therapeutics? | Stayble Therapeutics main competitors are Cannovum Cannabis, IO Biotech, GeNeuro, PharmaLundensis. |
| What is the current market cap of Stayble Therapeutics? | Stayble Therapeutics' current market cap is $896K. |
| Is Stayble Therapeutics profitable? | No, Stayble Therapeutics is not profitable. |
| What is the current EBITDA of Stayble Therapeutics? | Stayble Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Stayble Therapeutics? | Current EBITDA multiple of Stayble Therapeutics is (4.2x). |
| What is the current FCF of Stayble Therapeutics? | Stayble Therapeutics' last 12 months FCF is ($271K). |
| What is the current EV/FCF multiple of Stayble Therapeutics? | Current FCF multiple of Stayble Therapeutics is (2.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.